| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and raises the price target from $4 to $8.
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiv...
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus fo...
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.
